Monaco Asset Management SAM Invests $1.04 Million in Inogen, Inc $INGN

Monaco Asset Management SAM purchased a new stake in Inogen, Inc (NASDAQ:INGN) in the second quarter, according to its most recent filing with the SEC. The fund purchased 160,742 shares of the medical technology company’s stock, valued at approximately $1,037,000. Inogen comprises 0.1% of Monaco Asset Management SAM’s portfolio, making the stock its 28th biggest position.

Several other institutional investors and hedge funds have also made changes to their positions in INGN. Quarry LP bought a new position in Inogen during the fourth quarter worth $27,000. Torren Management LLC bought a new stake in Inogen during the fourth quarter valued at $51,000. Prelude Capital Management LLC bought a new stake in Inogen during the third quarter valued at $82,000. Corient Private Wealth LLC acquired a new stake in shares of Inogen during the fourth quarter worth $84,000. Finally, MetLife Investment Management LLC raised its holdings in shares of Inogen by 72.2% during the fourth quarter. MetLife Investment Management LLC now owns 12,699 shares of the medical technology company’s stock worth $85,000 after purchasing an additional 5,325 shares during the period. 89.94% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Inogen

In other news, EVP Boyer Jennifer M. Yi sold 10,938 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $6.60, for a total transaction of $72,190.80. Following the completion of the transaction, the executive vice president directly owned 5,039 shares in the company, valued at approximately $33,257.40. The trade was a 68.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 2.50% of the company’s stock.

Inogen Stock Performance

Inogen stock opened at $5.75 on Monday. Inogen, Inc has a one year low of $5.34 and a one year high of $9.13. The company has a 50-day simple moving average of $6.43 and a 200-day simple moving average of $6.37. The firm has a market capitalization of $152.60 million, a P/E ratio of -6.39 and a beta of 1.55.

Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Thursday, August 6th. The medical technology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. The firm had revenue of $95.08 million for the quarter, compared to the consensus estimate of $95.23 million. Inogen had a negative net margin of 6.94% and a negative return on equity of 13.17%. As a group, sell-side analysts forecast that Inogen, Inc will post -0.77 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Inogen in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

Inogen Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.